Best Cardiac and Vascular Disorders Companies in Netherlands
The 42 best Cardiac and Vascular Disorders companies in Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: NewAmsterdam Pharma.
Ranked: Best Cardiac and Vascular Disorders companies in Netherlands
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Acacia Designs Developer of medical monitoring devices. The company develops monitoring devices for patients affected by… | — | — | Acquired | — | 5 | — | — | — |
| 2 | Applied Biomedical Systems Developer of a medical device for screening Atrial Fibrillation | — | — | Funding Raised | Vincent Larik Founder & Director | — | — | — | — |
| 3 | Blue Medical Develops stents and catheters | — | — | Acqui-Hired | Ronald Horvers Founder & ex-CEO | — | — | 27 patents Drug‑eluting intravascular balloons and stents with expandable therapeutic coatings | — |
| 4 | CART-Tech Developer of cardiac regenerative therapy-based pacemaker | — | — | Funding Raised | Frebus van Slochteren Co-Founder & CTO | 8 | — | — | — |
| 5 | CFM Pharma Holding Organic Vanadium compounds for treatment of reperfusion injuries and burns | — | — | Unfunded | Jos Fleskens Founder & CEO | — | — | — | — |
| 6 | Chaperone Pharma Developer of therapies for treating aging-associated diseases | — | — | Unfunded | Herman Steen Founder & CEO | — | — | — | — |
| 7 | Comed A range of products for cardiovascular disorders | — | — | Deadpooled | Zhong Jie Pu Founder | — | — | 3 patents Cardiac apical occlusion devices for minimally invasive heart wall defect closure | — |
| 8 | De Haar Research Task Force Operator of a medical company intended to develop advanced cardiovascular service, imaging and innovative… | — | — | Private | — | 2 | — | — | — |
Top 12 Cardiac and Vascular Disorders companies in Netherlands
#1
Funding Raised · Nijmegen, Gelderland · founded 2018 · 18 employees$10.8Mraised▾
CardiacBooster provides percutaneous left ventricular assist devices. The company's devices are used to support the cardiac function of hemodynamically unstable patients. The device focus on ventricular support, cardiogenic shock, and high-risk PCI.
- Aug 2025Grant (prize money)$10.8M
- Dec 2019Grant (prize money)—
- Nov 2018Conventional Debt—
#2
Series B · Utrecht, Utrecht · founded 2016 · 21 employees$11.7Mraised▾
AMT MEDICAL is providing solutions for heart bypass surgery. Its AMT technology is based on total endoscopy coronary artery bypass surgery. With the use of a connector, laser catheter, and a small robot they make a small opening in the chest to perform surgery.
- Apr 2025Series B$25M
- Sep 2020Series A$11.7M
- Sep 2019Grant (prize money)$436.6K
- Grant (prize money)—
#3
Series A · Rotterdam, South Holland · founded 2018 · 6 employees$4.2Mraised▾
Kaminari Medical is developing a diagnostic solution for vulnerable plaque in the coronary arteries. The company has developed the ultrasound (ivus) and photoacoustic (pa) imaging that can provide information about plaque location and composition.
- Oct 2024Series A$4.2M
- Oct 2024Conventional Debt$1.6M
- Dec 2019Grant (prize money)—
#4
Seed · Naarden, North Holland · founded 2022 · 4 employees$2Mraised▾
Developer of gene therapy to cure genetic heart diseases. The lead program PHL-001 is a RNA-based therapeutic product that targets laminopathies, a rare inherited cardiomyopathy, and therapy resistant heart-failures.
- Nov 2024Seed$2M
#5
Public · Naarden, North Holland · founded 2019 · 17 employees$196Mraised▾
Developer of transformative therapeutic solutions for cardio-metabolic diseases. It has developed obicetrapib that is a small molecule, oral cholesterol ester transfer protein inhibitor. It is a protein inhibitor that targets Apolipoprotein B (ApoB) and low-density lipoprotein cholesterol (LDL-c) in the body. It is developing transformative therapies including obicetrapib for cardio-renal diseases.
- Jan 2021Series A$196M
#6
Seed · Oudkarspel, North Holland · founded 2021 · 2 employees$1.9Mraised▾
Provider of a temperature-sensing platform for cardiovascular monitoring. It offers a platform based on photonic technology with fiber optic sensors that allows reliable measurement of cardiovascular parameters, such as cardiac output and circulating blood volume, that can be used to optimize diagnosis and treatments.
- Feb 2024Seed$1.6M
- Jun 2023Seed$328.2K
#7
Seed · Eindhoven, North Brabant · founded 2007 · 13 employees$1.9Mraised▾
Developer of a regenerative stent for vascular disorders. The company has developed regenerative endovascular implants for the treatment of cardiovascular diseases that uses a catheter-based approach to restore arteries with invasive surgical intervention. The stent is made of a biodegradable supportive porous structure.
- Sep 2023Grant (prize money)$2.7M
- Apr 2022Seed$1.9M
- Aug 2018Grant (prize money)—
- Jun 2015Grant (prize money)—
#8
Acquired · Naarden, North Holland · founded 2012$13Mraised▾
Dezima Pharma develops novel products to treat dyslipidemic patients suffering from cardiovascular disease (CVD). Its lead product TA-8995 has been in licenced from Mitsubishi Tanabe Pharma Corporation and is cholesteryl ester transfer protein (CETP) inhibitor which is in Phase 2b clinical trial for dyslipidemia. The trails showed that it has reduced low-density lipoprotein cholesterol (LDL-C) by 45 to 48 percent compared to baseline. LDL-C reduction was consistent when administered as monotherapy or in combination with statins. It was acquired by Amgen in September 2015 for $300 million up front and $1.25 billion in milestones.
- Feb 2013Series A$13M
- Feb 2013Conventional Debt$5.8M
#9
Seed · Amsterdam, North Holland · founded 2016$334.2Kraised▾
Developer of implantable pacemaker therapies. The company is focusing on the development of clinically applicable biological pacemaker therapies which incorporate robust sensitivity to autonomic modulation to cure patients with a defective sinus node or Atrioventricular Node (AV).
- Oct 2023Grant (prize money)$992.5K
- Dec 2019Seed$334.2K
#10
Series A · Arnhem, Gelderland · founded 2008 · 17 employees$3.4Mraised▾
Developer of circulatory support systems for use in patients with heart failure. The products include iVAC 2L which is a transfemoral left ventricular assistance device, iVAC 3L-ST which is a minimally invasive short-term ventricular assistance device, and iVAC 3L, which is a mid-range minimal heart circulatory assist device.
- Sep 2021Series A—
- 2008Seed—
#11
Acquired · Amsterdam, North Holland · founded 2005$8.8Mraised▾
BMEYE is a engaged in the research and development of medical technologies for non-invasive cardiovascular monitoring. It offers finger arterial pressure and cardiac output technologies. The company's products include Finapres, a non-invasive continuous finger blood pressure monitor; Portapres, an ambulatory non-invasive continuous finger blood pressure monitor for measurements; Finometer, a stationary monitor with options for non-invasive brachial pressure and beat-to-beat hemodynamics; and BeatScope, a software package for the analysis of arterial pressure waveforms. Its products also comprise Modelflow, a model-based measurement method to compute the aortic flow waveform and cardiac output from an arterial blood pressure waveform; Space instrumentation, a version of finger blood pressure monitors; Cardiopres, an ambulatory device for research on the interaction of electrophysiology, hemodynamics, and respiration; and Oxyflow, a hemodynamics and oxygen delivery monitor for experimental applications. It also offers Nexfin, a non invasive blood pressure and cardiac output monitor, as well as ccNexfin for applications in various areas, such as cardiology, anesthesiology, sleep obser
- Oct 2009Series B$8.8M
- Jan 2009Series A—
- Dec 2006Seed—
#12
Deadpooled · Utrecht, Utrecht · founded 2014$6.8Mraised▾
Encare is focused in developing a new therapeutic antibody for the prevention of heart failure after acute myocardial infarction. The company is currently developing fibronectin-EDA monoclonal antibody for the prevention of heart failure
- Nov 2014PE$6.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.